Abstract
Background/Aims: Rats exposed to losartan during lactation exhibit progressive changes in renal function and structure. This study analyzed the early events in pups from dams that received losartan during lactation. Methods: Male Wistar rats from dams that received 2% sucrose (control, n = 25) or losartan (100 mg/kg/day) diluted in 2% sucrose (n = 33) during lactation were anesthetized 21 days after birth. Blood and urine samples were collected to assess renal function, and kidneys were removed for histological, immunohistochemical, Western blot, lipid peroxidation and glutathione analyses. Results: The group exposed to losartan exhibited increased albuminuria and fractional sodium and potassium excretion, decreased glomerular area and interstitial expansion. Immunohistochemical analyses demonstrated increased tubulointerstitial macrophage infiltration, apoptosis and increased vimentin and α-smooth-muscle-actin expression in animals exposed to losartan. In addition, the glomeruli of animals exposed to losartan exhibited increased peripheral desmin expression and reduced glomerular epithelial protein 1 and podocin expression compared to controls. Lastly, renal lipid peroxidation and glutathione levels were higher in the losartan-treated pups. Conclusion: Pups exposed to losartan during lactation exhibited adverse changes in renal function and structure, and tubulointerstitial inflammation at 21 days of age that were associated with apoptosis and oxidative stress.
Journal Section:
Original Paper
References
1.
Balbi APC, Marin ECS, Francescato HDC, Costa RS, Coimbra TM: MAPK and angiotensin II receptor in kidney of newborn rats from losartan-treated dams. Pediatr Nephrol 2008;23:1433–1444.
2.
Yosypiv IV, Schroeder M, El-Dahr SS: Angiotensin II type 1 receptor-EGF receptor cross-talk regulates ureteric bud branching morphogenesis. J Am Soc Nephrol 2006;17:1005–1014.
3.
Woolf AS, Winyard PJ: Advances in the cell biology and genetics of human kidney malformations. J Am Soc Nephrol 1998;9:1114–1125.
4.
Gomez RA, Tufro-McReddie A, Everett AD, Pentz ES: Ontogeny of renin and AT1 receptor in the rat. Pediatr Nephrol 1993;7:635–638.
5.
Gomez RA, Lynch KR, Sturgill BC, Elwood JP, Chevalier RL, Carey RM, Peach MJ: Distribution of renin mRNA and its protein in the developing kidney. Am J Physiol 1989;257:F850–F858.
6.
Tufro-McReddie A, Harrison JK, Everett AD, Gomez RA: Ontogeny of type 1 angiotensin II receptor gene expression in the rat. J Clin Invest 1993;91:530–537.
[PubMed]
7.
Millan MA, Carvallo P, Izumi S, Zemel S, Catt KJ, Aguilera G: Novel sites of expression of functional angiotensin II receptors in the late gestation fetus. Science 1989;244:1340–1342.
8.
Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE: Expression of AT2 receptors in the development rat fetus. J Clin Invest 1991;88:921–933.
9.
Daikha-Dahmane F, Levy-Beffe, Jugie M, Lenclen R: Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists. Pediatr Nephrol 2006;21:729–732.
10.
Gribouval O, Gonzáles M, Neuhaus T, Aziza J, Bieth E, Laurent N, Bouton JM, Feuillet F, Makni S, Ben Amar H, Laube G, Delezoide AL, Bouvier R, Dijoud F, Ollagnon-Roman E, Roume J, Joubert M, Antignac C, Gubler MC: Mutations in renin-angiotensin system genes are associated with autosomal recessive renal tubular dysgenesis. Nat Genet 2005;37:964–968.
11.
Niimura F, Labosky PA, Kakuchi J, Okubo S, Yoshida H, Oikawa T, Ichiki T, Naftilan AJ, Fogo A, Inagami T, Hogan BLM, Ichikawa I: Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 1995;96:2947–2954.
12.
Machado FG, Poppi EPB, Fanelli C, Malheiros DMAC, Zatz R, Fujihara CK: AT1 blockade during lactation as a model of chronic nephropathy: mechanisms of renal injury. Am J Physiol Renal Physiol 2008;294:F1345–F1353.
13.
Friberg P, Sundelin B, Bohman SO, Bobik A, Nilsson H, Wickman A, Gustafsson H, Petersen J, Adams MA: Renin-angiotensin system in neonatal rats: induction of a renal abnormality in response to ACE inhibition or angiotensin II antagonism. Kidney Int 1994;45:485–492.
[PubMed]
14.
Nigam SK, Aperia AC, Brenner BM: Development and maturation of the kidney; in Brenner BM, Rector FC (eds): The kidney: Physiology and Pathology, ed 5. Saunders, Philadelphia, 1996, pp 72–98.
15.
Reeves W, Caulfield JP, Farquhar MG: Differentiation of epithelial foot processes and filtration slits: sequential appearance of occluding junctions, epithelial polyanion and slit membranes in developing glomeruli. Lab Invest 1978;39:90–100.
[PubMed]
16.
Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431–2437.
[PubMed]
17.
Bagby SP, Holden W: Angiotensin II stimulates proliferation of aortic endothelial cells. Clin Res 1988;36:259A.
18.
Roberts AB, McCune BK, Sporn MB: TGF-β: Regulation of extracellular matrix. Kidney Int 1992;41:557–559.
[PubMed]
19.
Thiery JP, Duband JL, Dufour S, Savagner P, Imhof BA: Role of fibronectins in embryogenesis; in Mosher DF (ed): Biology of Extracellular Matrix: Fibronectin. San Diego, Academic Press, 1989, pp 181–212.
20.
Spence SG, Allen HL, Cukiersky MA, Manson JM, Robertson RT, Eydelloth RS: Defining the susceptible period of developmental toxicity for the AT1 selective angiotensin II receptor antagonist losartan in rats. Teratology 1995;51:367–382.
[PubMed]
21.
Spence SG, Zacchei AG, Lee LL, Baldwin CL, Berna RA, Mattson BA, Eydelloth RS: Toxicokinetic analysis of losartan during gestation and lactation in the rat. Teratology 1996;53:245–252.
22.
Laurell CB: Eletroimmuno assay. Scand J Clin Lab Invest 1972;124:21–23.
23.
Haygen HN: The determination of ‘endogenous creatinine’ in plasma and urine. Scand J Clin Lab Invest 1953;5:48–57.
[PubMed]
24.
Shih W, Hines WH, Nielasen EG: Effects of cyclosporin A on the development of incubated with the antibody immune-mediated interstitial nephritis. Kidney Int 1988;33:1113–1118.
[PubMed]
25.
Coimbra TM, Janssen U, Grone HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J: Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000;57:167–182.
[PubMed]
26.
Stambe C, Atkins RC, Hill PA, Nikolic-Paterson DJ: Activation and cellular localization of the p38 and JNK MAPK pathways in rat crescentic glomerulonephritis. Kidney Int 2003;64:2121–2132.
[PubMed]
27.
Hartree EF: Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem 1972;48:422–427.
[PubMed]
28.
Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493–501.
[PubMed]
29.
Buege JA, Aust SD: Microsomal lipid peroxidation. Methods Enzymol 1978;52:302–310.
[PubMed]
30.
Liu J, Yeo HC, Doniger SJ, Ames BN: Assay of aldehydes from lipid peroxidation: gas chromatography-mass spectrometry compared to thiobarbituric acid. Anal Biochem 1997;245:161–166.
31.
Sedlak J, Lindsay RH: Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968;5:192–205.
32.
Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C: NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000;24:349–354.
[PubMed]
33.
Wharram BL, Goyal M, Gillespie PJ, Wiggins JE, Kershaw DB, Holzman LB, Dysko RC, Saunders TL, Samuelson LC, Wiggins RC: Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate. J Clin Invest 2000;106:1281–1290.
[PubMed]
34.
Kim YH, Goyal M, Wharram WB, Wiggins J, Kershaw D: Wiggins R: GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis. A marker of acute podocyte injury. Nephron 2002;90:471–476.
35.
McCausland JE, Bertram JF, Ryan GB, Alcorn D: Glomerular number and size following chronic angiotensin II blockade in the postnatal rat. Exp Nephrol 1997;5:201–209.
[PubMed]
36.
Naruse K, Fujieda M, Miyazaki E, Hayashi Y, Toi M, Fukui T, Kuroda N, Hiroi M, Kurashige T, Enzan H: An immunohistochemical study of developing glomeruli in human fetal kidneys. Kidney Int 2000;57:1836–1846.
37.
El Nahas AM, Muchaneta-Kubara EC, Zhang G, Adam A, Goumenos D: Phenotypic modulation of renal cells during experimental and clinical renal scarring. Kidney Int 1996;54:S23–S27.
38.
Madsen K, Marcussen N, Pedersen M, Kjaersgaard G, Facemire C, Coffman TM, Jensen BL: Angiotensin II promotes development of the renal microcirculation through AT1 receptors. J Am Soc Nephrol 2010;21:448–459.
39.
Eardley KS, Cockwell P: Macrophages and progressive tubulointerstitial disease. Kidney Int 2005;68:437–455.
[PubMed]
40.
Jankov RP, Negus A, Tanswell AK: Antioxidants as therapy in the newborn: some words of caution. Pediatr Res 2001;50:681–687.
[PubMed]
41.
Cambonie G, Comte B, Yzydorczyk C, Ntimbane T, Germain N, Lê NL, Pladys P, Gauthier C, Lahaie I, Abran D, Lavoie JC, Nuyt AM: Antenatal antioxidant prevents adult hypertension, vascular dysfunction, and microvascular rarefaction associated with in utero exposure to a low-protein diet. Am J Physiol Regul Integr Comp Physiol 2007;292:R1236–R1245.
42.
Francescato HDC, Costa RS, Scavone C, Coimbra TM: Parthenolide reduces cisplatin-induced renal damage. Toxicology 2007;230:64–75.
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.
